Investment Rating - The investment rating for Mixue Group has been downgraded to "Neutral" [2][4][13]. Core Insights - The report highlights that in 2026, the withdrawal of domestic subsidy policies and the shift in consumer purchasing habits towards online channels will increase the demands on the company's online operational capabilities against a high base. The company will adhere to a "quality-first" development strategy and slow down the pace of new store expansion while focusing on upgrading product raw materials and supply chains, which may pressure gross profit margins [4][14][15]. - Revenue projections for Mixue Group are estimated at RMB 37.28 billion, RMB 42.61 billion, and RMB 48.85 billion for 2026, 2027, and 2028 respectively, reflecting year-on-year growth rates of 11.1%, 14.3%, and 14.6%. Net profit attributable to the parent company is expected to be RMB 6.19 billion, RMB 7.26 billion, and RMB 8.58 billion for the same years, with corresponding growth rates of 5.1%, 17.2%, and 18.3% [4][13][16]. - The company is facing operational challenges due to a shift in consumer habits towards online consumption, which has impacted its traditional offline store model. Management anticipates pressures on store turnover and profitability in 2026 and is implementing measures to drive revenue and profit growth [5][14][15]. Financial Projections - For the fiscal years 2026 to 2028, the projected diluted EPS is RMB 16.38, RMB 19.18, and RMB 22.67, with corresponding P/E ratios of 15.5X, 13.2X, and 11.2X [4][16]. - The company reported a total revenue of RMB 33.56 billion for 2025, a year-on-year increase of 35.2%, and a net profit of RMB 5.93 billion, up 33.1% year-on-year [16]. Operational Adjustments - The company is actively adjusting its operations in Southeast Asia, particularly in Indonesia and Vietnam, to ensure long-term profitability and address deficiencies in early store operations. The goal is to achieve net growth in overseas store numbers for 2026 [6][15]. - As of the end of 2025, Mixue Group operated nearly 4,500 overseas stores, primarily in Southeast Asia, and is also expanding into other regions, including Central Asia and the United States [6][15].

Investment Rating - The investment rating for Xiaocaiyuan International has been downgraded to "Neutral" with a target price of HKD 6.79, indicating a modest upside of 0.2% from the current price of HKD 6.78 [2][3]. Core Insights - Xiaocaiyuan is expected to achieve revenue growth in 2026-2028, with projected revenues of RMB 5.707 billion, RMB 6.970 billion, and RMB 7.852 billion, representing year-on-year growth rates of +6.8%, +22.1%, and +12.7% respectively. Net profit is forecasted at RMB 634 million, RMB 783 million, and RMB 898 million, with year-on-year growth rates of -11.3%, +23.4%, and +14.7% [3][13]. - The company is entering a strategic adjustment year in 2026, focusing on proactive price reductions for dine-in services to enhance its "value-for-money" positioning, which is expected to lead to a decrease in gross margin from 70.4% in 2025 to 65.0% [5][15]. - The 88VIP membership program has shown strong initial performance, adding over 410,000 members within two and a half months and achieving a repurchase rate exceeding 40%, which is expected to drive customer traffic during the adjustment year [6][16]. Revenue and Profit Forecast - For 2025, Xiaocaiyuan reported a revenue of RMB 5,345.1 million, reflecting a year-on-year increase of 2.6%. The net profit for the same year was RMB 715.1 million, up 23.2% year-on-year, with a net margin of 13.4% [4][14]. - The revenue breakdown for 2026 estimates dine-in revenue at RMB 3,482.1 million and delivery revenue at RMB 2,204.9 million, both showing a year-on-year growth of 6.8% [10][12]. Strategic Initiatives - The company is implementing a "premium delivery" strategy to optimize its delivery mix, capping delivery orders at 30% during peak hours to maintain quality [5][15]. - A new smart factory in Ma'anshan is set to commence operations in the first half of 2026, which is expected to enhance cost control and operational efficiency [8][17]. - The new store model has demonstrated high efficiency, with a breakeven period of approximately one month and a payback period of about 12 months, indicating strong replicability [18].

Investment Rating - The report maintains an "Outperform" rating for Weilong Delicious Global Holdings [2][7]. Core Insights - The full-year 2025 performance met expectations, with a dividend payout ratio lowered to 61.4% from 99.0% in 2024 [3][10]. - In 2H25, Weilong recorded revenue of RMB 3.74 billion, representing a year-on-year increase of 18.5%, with a gross profit margin of 48.8% [10][11]. - The vegetable products category, particularly Konjac Snacks, achieved revenue of RMB 2.397 billion in 2H25, a 26% year-on-year growth, marking over 62.4% of total revenue for the first time [3][10]. - The company plans to focus on innovation and efficiency improvements, targeting a 15% revenue growth in 2026 [12][13]. Financial Performance Summary - Revenue projections for 2026-2028 are RMB 8.34 billion, RMB 9.52 billion, and RMB 10.72 billion, with year-on-year growth rates of 15.4%, 14.2%, and 12.6% respectively [13]. - Net profit attributable to the parent company is expected to be RMB 1.67 billion, RMB 1.89 billion, and RMB 2.20 billion for 2026-2028, reflecting growth rates of 17.5%, 12.9%, and 16.6% [13]. - The projected P/E ratios for 2026-2028 are 12.1X, 10.9X, and 9.5X [13]. Market Strategy and Operations - The company is advancing omnichannel integration, with offline revenue reaching RMB 3.33 billion in 2H25, a 12% year-on-year increase, while online revenue was RMB 411 million, also up 12% [11][12]. - Future strategies include localized operations in overseas markets, particularly in Southeast Asia and Japan, and capital expenditure focused on new product R&D and production capacity upgrades [12][13].

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The company expects to recognize out-licensing revenue progressively starting in 2026, with significant upfront payments from collaborations with Roche and Takeda [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [19][21] Financial Summary - Revenue projections for FY26 and FY27 have been raised to RMB 17.8 billion and RMB 20.5 billion, respectively, along with net profit forecasts of RMB 2.3 billion and RMB 3.5 billion [10][21] - The company’s selling expenses increased by 31% year-on-year to RMB 5.7 billion, while R&D expenses decreased by 2% to RMB 2.6 billion [3][15] - The report indicates a strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to drive further growth in 2026 [4][16]

Investment Rating - The report assigns an "Outperform" rating for China Resources Mixc Lifestyle Services, expecting a relative return exceeding 10% over the next 12-18 months [21]. Core Insights - The company achieved a revenue of RMB 18.02 billion in 2025, a year-on-year increase of 5.1%, with core net profit reaching RMB 3.95 billion, up 13.7%, resulting in a net profit margin of 21.9% [1][8]. - Operating cash flow covered 103.3% of the shareholders' attributable core net profit, and the annual dividend per share increased by 12.7% to RMB 1.731, marking three consecutive years of 100% distribution of core net profit [1][8]. Summary by Sections Business Performance - The commercial and property segments generated revenues of RMB 6.91 billion and RMB 10.85 billion, reflecting year-on-year growth of 10.1% and 1.1%, respectively. The overall gross profit margin improved by 2.5 percentage points to 35.5% [2][9]. - The gross profit margin for the commercial segment rose by 2.9 percentage points to 63.1%, while the property segment's margin increased by 1.0 percentage point to 18.0% [2][9]. Shopping Mall and Office Performance - Shopping mall retail sales grew by 23.7% year-on-year, with comparable growth of 12.2%, significantly outpacing social retail sales growth. The total foot traffic reached 2.04 billion, up 32.7% year-on-year [3][10]. - Rental income from landlords increased by 16.9% to RMB 30.7 billion, and NOI grew by 17.8% to RMB 20.1 billion, with an NOI margin of 65.7% [3][10]. Property Management Strategy - The property management channel added 35.3 million square meters of third-party contracted area, with 80% located in first- and second-tier cities. The total area under management reached 426 million square meters, a year-on-year increase of 3.2% [4][11]. - Customer satisfaction in community spaces improved to 92.71 points, and the collection rate remained stable at nearly 100% for existing projects [4][11]. Strategic Planning - The company outlined its "15th Five-Year" strategic plan, aiming to enhance profitability and quality leadership. The commercial management business targets the addition of 100 new shopping centers and aims for a compound growth rate of revenue and profit exceeding 10% [5][12]. - For 2026, the company anticipates double-digit growth in both revenue and core net profit, with same-store sales expected to achieve mid-to-high single-digit growth [6][13].

Investment Rating - The report maintains an "OUTPERFORM" rating for SoYoung (SY US) with a target price of US$10.20, while the current price is US$2.70 [2]. Core Insights - The company is expected to maintain high growth in its aesthetic treatment services, with revenue projections for FY26 reaching RMB 1,542 million, reflecting a significant increase [4]. - The management plans to open at least 35 new stores in 2026, focusing on expanding in first and second-tier cities, which is anticipated to enhance revenue growth [4]. - Despite challenges in traditional business segments, the overall revenue for FY26 is projected to grow by 43%, driven primarily by the aesthetic treatment services [5]. - The report highlights the company's unique competitive advantages, including a strong brand, operational efficiency, and a clear expansion roadmap, which supports the positive outlook [5]. Financial Summary - Revenue for FY26 is estimated at RMB 2,174 million, representing a 43% increase from the previous year, with a projected net profit of RMB 10 million in FY27 [8]. - The gross profit margin is expected to stabilize around 29% for FY26, with operational efficiency being a key focus for the management [4][5]. - The company is projected to achieve breakeven by Q4 FY26, with a narrowed adjusted net loss of approximately RMB 198 million for FY26 [5][8].

Investment Rating - The report does not explicitly state the investment rating for Hansoh Pharma Core Insights - Hansoh Pharma achieved revenue of RMB 15.0 billion in FY25, representing a 23% year-over-year increase. Innovative drug revenue reached RMB 10.2 billion (+30% YoY), while generic drug revenue was RMB 2.7 billion (-4% YoY). Collaboration revenue amounted to RMB 2.1 billion (+35% YoY) [1][4][5] - The proportion of innovative drug and collaboration income increased to 82% of total revenue, indicating a strong focus on innovative products [1][4] - The gross margin stood at 90.0%, down 1 percentage point year-over-year, while the operating profit margin increased by 4 percentage points to 36% due to improved selling expense ratios [5] - The net profit attributable to shareholders was RMB 5.56 billion, reflecting a 27% increase year-over-year, aligning with market expectations [1][5] Segment Analysis - Oncology revenue was RMB 10.0 billion (+23% YoY), accounting for 66% of total revenue. Anti-infective revenue was RMB 1.6 billion (+8% YoY), making up 12% of total revenue. Central nervous system revenue was RMB 1.3 billion (-5% YoY), representing 11% of total revenue. Metabolic and other diseases revenue was RMB 2.2 billion (+67% YoY), also accounting for 11% of total revenue [3][8] - Key milestones include the approval of Aumolertinib for first-line treatment in January 2026, expected to be included in the National Reimbursement Drug List in 2027. The company also completed three overseas licensing deals with a total transaction value exceeding USD 4.54 billion [6][8] - In 2025, the company advanced 8 new innovative drug candidates into clinical development and initiated 7 pivotal Phase III registrational clinical trials [6][8]

Investment Rating - The report maintains an "Outperform" rating for Medlive Technology [2][7] Core Insights - The company achieved a revenue of RMB 642 million in FY2025, representing a growth of 15.0%, primarily driven by the precision marketing segment [3][14] - The gross margin for FY2025 was 60.0%, an increase of 1.4 percentage points, indicating improved operational profitability [4][16] - The company is leveraging AI capabilities to enhance its product offerings, with a notable increase in monthly active users (MAU) to over 3.02 million, reflecting a growth of 14.0% [5][17] Financial Performance Summary - Revenue for FY2025 was RMB 642 million, with a breakdown as follows: - Precision marketing and enterprise solutions: RMB 595 million (+16.0%) - Medical knowledge solutions: RMB 19 million (+6.0%) - Intelligent patient management solutions: RMB 28.7 million (+2.4%) [3][14] - The adjusted net profit for FY2025 was RMB 342 million, a growth of 5.7%, with an adjusted net profit margin of 53.3% [4][16] - The company expects revenue for FY2026 and FY2027 to reach RMB 733 million and RMB 825 million, respectively, with year-on-year growth rates of 14.2% and 12.6% [7][18] Product and Market Development - The company launched an "AI + Medicine" product matrix, which includes MedSeeker, MedPaper, and MedAssister, enhancing its service offerings to pharmaceutical companies [5][17] - The management anticipates a 20% increase in marketed products in 2026, which is expected to support revenue growth [7][18]

Investment Rating - The report maintains an "Outperform" rating for Haidilao International Holding [2][3] Core Insights - Haidilao's revenue is projected to reach RMB 45.06 billion in 2026, with a year-on-year growth of 4.2%, and net profit is expected to be RMB 4.36 billion, reflecting a growth of 7.7% [3][13] - The Pomegranate Plan, which includes new brands like seafood stalls and sushi, is seen as a critical avenue for future growth, with significant revenue contributions expected [5][15] - The delivery business has shown strong growth, with a revenue increase of 111.9% year-on-year, becoming a key pillar of revenue expansion [6][16] Financial Performance Summary - For 2025, Haidilao's restaurant revenue was RMB 37.54 billion, down 7.1% year-on-year, while the average spend per guest slightly increased from RMB 97.5 to RMB 97.7 [4][14] - The company plans to maintain a mid-single-digit pace for new store openings in 2026, focusing on optimizing existing stores [4][14] - The delivery segment is expected to continue its growth trajectory, contributing significantly to overall revenue and profit [6][8] Management and Strategic Focus - Zhang Yong's return as CEO aims to enhance strategic execution and organizational efficiency, particularly in expanding the multi-brand strategy under the Pomegranate Plan [8][17] - The report emphasizes the importance of validating the scalability and profitability of new brands in 2026, marking it as a pivotal year for the company [5][19] - Key investment focuses include the recovery of the flagship brand's table turnover and average spend, as well as the progress of new brand rollouts [19]

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics [2][3]. Core Insights - The company achieved a revenue of RMB 5.05 billion in 2025, reflecting a year-on-year growth of 30%, and net profit attributable to the parent was RMB 1.20 billion, up 36.7% year-on-year [4][12]. - Management has set a growth guidance of 30% for the upcoming years, with expectations for revenue to reach RMB 6.50 billion, RMB 8.15 billion, and RMB 9.97 billion in 2026, 2027, and 2028, respectively [3][11]. - The company’s net profit margins are projected to remain robust at 23.3%, 22.9%, and 22.7% for the years 2026 to 2028 [11]. Financial Performance - Revenue for 2025 was RMB 5.05 billion, slightly below expectations by 1.0%, while net profit exceeded expectations by 0.2% [4][12]. - The gross profit margin for 2025 was reported at 84.2%, which is an improvement of 0.3 percentage points compared to expectations [8]. - The company’s diluted EPS for 2025 was RMB 2.46, with a projected increase to RMB 3.09 in 2026 [2][10]. Product Performance - Key products such as the Luxury Caviar Cushion and the Luxury Caviar Mask have shown strong sales, contributing significantly to revenue [5][13]. - The color cosmetics segment generated RMB 3.00 billion in revenue for 2025, while skincare revenue reached RMB 1.87 billion, both showing substantial year-on-year growth [14][15]. - New product launches in 2026 are expected to further enhance sales, particularly in the skincare and eye makeup categories [5][13]. Market Position and Strategy - The company has successfully increased its online sales, which accounted for over 50% of total revenue for the first time, with a year-on-year growth of 38.8% [6][15]. - Offline same-store sales grew by 16%, indicating strong brand loyalty and customer retention [6][15]. - Mao Geping Cosmetics aims to continue expanding its high-end market presence while maintaining a clear strategy focused on online customer acquisition and premium product offerings [14][15].